Most Read

Located in Frederick, Maryland, the 275,000ft2 facility will produce the FDA-approved CAR T-cell therapy which is utilised for the treatment of blood cancer. The CAR T-cell therapies are

As part of the collaboration, the companies will jointly develop new antibody drugs which can significantly expand the immunotherapy’s potential in improving the lives of cancer and other

Bionova Scientific is a portfolio company of private investment firm Great Point Partners. It offers contract process development services as well as GMP-compliant contract manufacturing services to biopharmaceutical

The drug is claimed to be the first and only oral MET inhibitor recommended to treat advanced NSCLC harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping

Padcev is indicated as a monotherapy to treat locally advanced or metastatic urothelial cancer adult patients who previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor. The regulatory

Led by Deerfield Management, the funding round saw participation from existing investors Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision, an ophthalmology-focused investment platform backed by KKR,

Initially executed in 2017, the agreement grants exclusive rights to Kyowa Kirin for the development and commercialisation of Ardelyx’s tenapanor to treat cardiorenal diseases including hyperphosphatemia in Japan.

The clinical trial is designed for assessing GRC 54276’s tolerability and safety as a monotherapy, as well as in combination with checkpoint inhibitors in these patients. GRC 54276

HBM7022 has been produced from HBM’s HCAb Based Immune Cell Engagers (HBICE) Platform. It crosslinks tumour and T cells by targeting a tumour-associated antigen (Claudin18.2) and CD3 that